N. B. KURNICK, M.D.; KARL R. PALEY, M.D.; MACK H. FIEBER, M.D.; D. K. ADLER, M.D.
Our purpose in this paper is to summarize the clinical literature on the use of the nitrogen mustards in malignant diseases,—the indications, hazards, effects and side-effects. Our experience with 64 additional cases is included.
Reports on the clinical application of the nitrogen mustards in the treatment of neoplastic diseases have recently been released.1 Rhoads4 summarized the results of therapy as follows:
1. Methyl-bis (β-chloroethyl) amine hydrochloride (designated HN2) appears to be preferable to tris (β-chloroethyl) amine hydrochloride as venous thrombosis is less likely to follow at the injection site.
2. The recommended dosage is 0.1 mg. per kilogram intravenously on
N. B. KURNICK, KARL R. PALEY, MACK H. FIEBER, D. K. ADLER. TREATMENT OF MALIGNANT DISEASE WITH NITROGEN MUSTARD(TREATMENT OF MALIGNANT DISEASE WITH NITROGEN MUSTARD*). Ann Intern Med. 1949;30:974–1003. doi: 10.7326/0003-4819-30-5-974
Download citation file:
Published: Ann Intern Med. 1949;30(5):974-1003.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use